The stock of Avidity Biosciences Inc (NASDAQ: RNA) has decreased by -9.42 when compared to last closing price of 29.52. Despite this, the company has experienced a -16.70% fall in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-01 that SAN DIEGO, April 1, 2025 /PRNewswire/ — Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the “Events and Presentations” page in the “Investors” section of Avidity’s website at https://aviditybiosciences.investorroom.com/events-and-presentations.
Is It Worth Investing in Avidity Biosciences Inc (NASDAQ: RNA) Right Now?
The stock has a 36-month beta value of 1.01. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RNA is 111.14M, and at present, short sellers hold a 14.51% of that float. On April 02, 2025, the average trading volume of RNA was 1.38M shares.
RNA’s Market Performance
RNA stock saw a decrease of -16.70% in the past week, with a monthly decline of -8.49% and a quarterly a decrease of -11.19%. The volatility ratio for the week is 5.60%, and the volatility levels for the last 30 days are 6.84% for Avidity Biosciences Inc (RNA). The simple moving average for the past 20 days is -13.91% for RNA’s stock, with a -31.27% simple moving average for the past 200 days.
Analysts’ Opinion of RNA
Many brokerage firms have already submitted their reports for RNA stocks, with Citigroup repeating the rating for RNA by listing it as a “Buy.” The predicted price for RNA in the upcoming period, according to Citigroup is $70 based on the research report published on March 13, 2025 of the current year 2025.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see RNA reach a price target of $72. The rating they have provided for RNA stocks is “Outperform” according to the report published on March 12th, 2025.
Scotiabank gave a rating of “Sector Outperform” to RNA, setting the target price at $70 in the report published on March 07th of the current year.
RNA Trading at -14.93% from the 50-Day Moving Average
After a stumble in the market that brought RNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.25% of loss for the given period.
Volatility was left at 6.84%, however, over the last 30 days, the volatility rate increased by 5.60%, as shares sank -6.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -7.54% lower at present.
During the last 5 trading sessions, RNA fell by -16.70%, which changed the moving average for the period of 200-days by -30.29% in comparison to the 20-day moving average, which settled at $31.06. In addition, Avidity Biosciences Inc saw -8.05% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RNA starting from Hughes Steven George, who sale 9,578 shares at the price of $31.06 back on Mar 20 ’25. After this action, Hughes Steven George now owns 72,850 shares of Avidity Biosciences Inc, valued at $297,491 using the latest closing price.
Boyce Sarah, the President and CEO of Avidity Biosciences Inc, sale 31,540 shares at $31.06 during a trade that took place back on Mar 20 ’25, which means that Boyce Sarah is holding 305,871 shares at $979,563 based on the most recent closing price.
Stock Fundamentals for RNA
Current profitability levels for the company are sitting at:
- -34.77 for the present operating margin
- 0.88 for the gross margin
The net margin for Avidity Biosciences Inc stands at -29.58. The total capital return value is set at -0.26. Equity return is now at value -33.47, with -29.40 for asset returns.
Based on Avidity Biosciences Inc (RNA), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -44.24.
Currently, EBITDA for the company is -378.94 million with net debt to EBITDA at 0.57. When we switch over and look at the enterprise to sales, we see a ratio of 275.43. The receivables turnover for the company is 0.39for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 15.73.
Conclusion
To sum up, Avidity Biosciences Inc (RNA) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
